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Abstract
Background: Comorbidity is known to increase risk of death in cancer patients, both Aboriginal and non-Aboriginal.
The means of measuring comorbidity to assess risk of death has not been studied in any depth in Aboriginal patients
in Australia. In this study, conventional and customized comorbidity indices were used to investigate effects of
comorbidity on cancer survival by Aboriginal status and to determine whether comorbidity explains survival disparities.
Methods: A retrospective cohort study was undertaken using linked population-based South Australian Cancer
Registry and hospital inpatient data for 777 Aboriginal people diagnosed with primary cancer between 1990 and 2010
and 777 randomly selected non-Aboriginal controls matched by sex, birth year, diagnosis year and tumour type.
A customised comorbidity index was developed by examining associations of comorbid conditions with 1-year
all-cause mortality within the Aboriginal and non-Aboriginal patient groups separately using Cox proportional hazard
model, adjusting for age, stage, sex and primary site. The adjusted hazard ratios for comorbid conditions were used as
weights for these conditions in index development. The comorbidity index score for combined analyses was the sum
of the weights across the comorbid conditions for each case from the two groups.
Results: The two most prevalent comorbidities in the Aboriginal cohort were “uncomplicated” hypertension (13.5%)
and diabetes without complications (10.8%), yet in non-Aboriginal people, the comorbidities were “uncomplicated”
hypertension (7.1%) and chronic obstructive pulmonary disease (4.4%). Higher comorbidity scores were associated with
higher all-cause and cancer-specific mortality. The new index showed minor improvements in predictive ability and
model fit when compared with three common generic comparison indices. After accounting for the competing risk of
other deaths, stage at diagnosis, socioeconomic status, area remoteness and comorbidity, the increased risk of cancer
death in Aboriginal people remained.
Conclusions: Our new customised index performed at least as well, although not markedly better than the generic
indices. We conclude that in broad terms, the generic indices are reasonably effective for adjusting for comorbidity
when comparing survival outcomes by Aboriginal status. Irrespective of the index used, comorbidity has a negative
impact on cancer-specific survival, but this does not fully explain the lower survival in Aboriginal patients.
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Background
Many cancer patients have concurrent chronic disease or
conditions, commonly referred to as comorbidity. The risk
of having comorbidity increases with age and can influ-
ence treatment choices [1–3]. Comorbidity has been
shown to affect cancer diagnosis and treatment practices,
and lead to an increased risk of hospitalisation, reduced
quality of life, increased mortality, and potentially in-
creased healthcare costs [3–5].
Comorbidity is an important determinant of poorer can-
cer outcomes [3], and potentially more so in Aboriginal
than non-Aboriginal populations, due to a higher preva-
lence of comorbid conditions (e.g., diabetes, renal disease,
injuries, diseases of the respiratory and cardiovascular sys-
tems, and infectious diseases) [6–10] .
Given the clinical importance of comorbidity and its
high prevalence in ageing cancer populations, it is essen-
tial to have a measure for quantifying likely effects on
cancer outcomes. Comorbidity indices have been devel-
oped to measure the extent of comorbid conditions and
to quantify their impact on mortality [11–13]. These in-
dices are often used for risk stratification or adjustment
when comparing disease-specific survival or other health
outcomes across different groups. The validity of these
indices can vary, however, depending on the population,
the diseases involved, the data sources and outcome
measures [11–13].
Commonly used indices include the Charlson Comor-
bidity Index (CCI) and Elixhauser Comorbidity Index
(ECI) [14, 15]. These indices were developed using gen-
eral in-hospital patients to summarise risk of all-cause
mortality at 1 year and in-hospital mortality due to co-
morbidity. Later, van Walraven developed weights for
Elixhauser conditions using administrative data based on
in-hospital mortality [16].
As the CCI and ECI were developed over two decades
ago, and for limited purposes in general hospital patients,
they may be sub-optimal indices of comorbidity for con-
temporary cancer populations. Previous studies have
shown that ECI had a slightly better performance than
CCI [13, 16]. Another population-based cancer specific
index, which was developed based on the impact of co-
morbidity on non-cancer mortality, Cancer, Care and Co-
morbidity (C3), showed a superior model fit when
compared to CCI [17]. Although cancer-specific, the C3
was not designed to meet the needs of an Australian
Aboriginal cohort.
Due to the potential limitations of currently available
comorbidity indices, and the lack of a gold standard
method of measuring comorbidity [11–13], this study was
undertaken to: (1) describe the prevalence of comorbidi-
ties in Aboriginal and non-Aboriginal cancer populations
in South Australia; and (2) develop a customised index for
assessing the impact of this comorbidity on mortality by
Aboriginal status. The utility of this index is demonstrated
empirically by predicting excess mortality risk from co-
morbidity in a matched cohort and by comparing its pre-
dictive effects with that of generic indices. To the best of
the authors’ knowledge, this is the first time a comorbidity
index has been developed and customised for an Austra-
lian cancer cohort by Aboriginal status.
Methods
Data sources and linkage
Cancer data were extracted from South Australian Can-
cer Registry (SACR) and linked in-hospital data from all
hospitals in SA, as incorporated in the South Australia
Inpatient Hospital Separations (ISAAC) database. SACR
is a population-based cancer registry that collects data
on all cancers diagnosed in South Australia (excluding
non-melanoma skin cancer). Notification of cancer is
mandatory from pathology laboratories, radiotherapy
centres, hospitals and the Registrar of Births, Deaths and
Marriages (BDM). The SACR also collects mortality by
routine linkage to South Australian death files and for
deaths occurring outside of South Australia, to the Na-
tional Death Index at the Australian Institute of Health
and Welfare. Record linkage of data from the SACR,
ISAAC, and BDM was conducted by SANT Data Link,
with supplementary linkage to inpatient data undertaken
by the SA Government Epidemiology Branch [18].
Study population and variables
Due to small population numbers, Aboriginal and Torres
Strait Islander people were combined and respectfully re-
ferred to as Aboriginal people in this study. All registered
cancer cases in Aboriginal people diagnosed between 1990
and 2010 were included in this study. Aboriginal status of
cases was checked through cross-referencing with other
databases to reduce classification bias [18, 19]. Emphasis
was placed on specificity at the expense of sensitivity to en-
sure that non-Aboriginal people were not misclassified as
Aboriginal. Aboriginal cancer cases were paired with ran-
domly selected control cancer cases in non-Aboriginal
people, with matching for birth year, sex, primary cancer
site and year of diagnosis. The matching process has been
described in detail elsewhere [18]. The matched cohort was
used for two purposes; firstly, to develop a general popula-
tion cancer specific comorbidity index (PCSCI) with ac-
count taken of Aboriginal status, and secondly, to test the
utility of the PCSCI for explaining survival differences be-
tween Aboriginal and non-Aboriginal people with cancer.
Demographic and clinical data were extracted from
the SACR, including age at diagnosis (years), sex, pri-
mary site of cancer, tumour grade, degree of spread
(local, regional, distant and unknown), and diagnostic
period (1990–1999 or 2000–2010). Remoteness was de-
rived from residential postcode at diagnosis [20], and
Pule et al. BMC Health Services Research  (2018) 18:776 Page 2 of 8
indices of socioeconomic disadvantage measured by
postcode categorised in quintiles (Q1: most disadvan-
tage; Q5: least disadvantage) [21]. Death dates were in-
cluded, plus causes of death coded as cancer or
non-cancer by registry staff.
The International Classification of Diseases 10th Revi-
sion (ICD-10) was used to code comorbidity data obtained
by extraction from patients’ in-hospital records for the 5
years preceding the primary cancer diagnosis. Comorbid
conditions that were rarely reported in our population
(prevalence not greater than 0.5%) were excluded. All can-
cer cases were followed-up from date of diagnosis to date
of death, or to censoring on 31st December 2011, which-
ever came first. Patients with no record of death were as-
sumed to be alive at the end of the follow-up period. For
comorbidity index development, 1-year all-cause mortality
was used as the outcome. For the validation of the index
and subsequent survival analyses, both all-cause and
cancer-specific mortality were outcomes of interest.
A Stata module was used to calculate CCI and ECI
index scores based on originally developed CCI weights
and modified to include ECI weights developed by van
Walraven et al. [14–16, 22, 23]. Similarly, a SAS macro de-
veloped by Sarfati et al. [17] was converted into Stata and
used to calculate C3 index score based on original weights
developed for the 42 conditions in the all-sites C3 index.
Scores for each participant were calculated separately for
the respective indices as the sum of all the weights for the
conditions recorded excluding cancers. The scores were
treated as continuous variables for analysis and only cate-
gorised for descriptive purposes.
Statistical analysis
Data were prepared using Stata version 14 (StataCorp,
College Station, Texas) [24]. Initially an endeavour was
made to rectify any missing data or errors by checking
with data sources. Descriptive analyses of demographic
and clinical characteristics were then made by Aboriginal
status. Differences by Aboriginal status were tested using
McNemar’s test for binary variables and Wilcoxon rank
sum test for ordinal variables in the matched cohort.
Development of a general population-based cancer-specific
comorbidity index (PCSCI)
To develop a general PCSCI which can be applied in Abo-
riginal only, or combined Aboriginal and non-Aboriginal
cohorts, the matched cohort was first split into Aboriginal
and non-Aboriginal cases. Comorbidities were identified
separately for each group. Cox proportional hazard
models were fitted separately for each comorbid condition
in the Aboriginal cohort and non-Aboriginal cohort re-
spectively to avoid overfitting [17]. Models were adjusted
for age, degree of spread (summary stage), sex and pri-
mary site, and the association of each comorbid condition
with 1-year all-cause mortality determined. Adjusted haz-
ard ratios (aHR) < 1 were assigned a “0” and those > = 1
were rounded to the nearest whole number. These aHRs
were then assigned as weights for the respective Aborigi-
nal and non-Aboriginal models. Weights thus obtained
were summed across the two groups for each person to
obtain a measure of comorbidity burden for the entire co-
hort (referred to as the PCSCI score) and used in subse-
quent analyses. Proportionality, a key Cox proportional
hazards assumption, was assessed using Schoenfeld’s re-
siduals and found to be met.
Internal validation of the index
Bootstrapping was used to generate multiple samples from
the matched cohort for validating and comparing the cus-
tomised index performance with that of three pre-existing
indices (two generic and one cancer specific). The per-
formance of PCSCI, CCI, ECI and C3 indices, relative to
baseline models for all-cause and cancer-specific mortality
(adjusting for age and stage) was evaluated for discrimina-
tive ability using Harrell’s concordance statistic (C-index)
using bootstrapping (1000 iterations) [25, 26], and the
Akaike Information Criterion (AIC) for model fit using a
stratified Cox regression model [27].
The utility of PCSCI in explaining variation in survival
Models that included Aboriginal status were adjusted for
remoteness, area level socioeconomic status (SES), degree
of spread and respective measures of comorbidity (i.e.,
PCSCI, CCI, ECI and C3). Interactions between Aborigi-
nality and remoteness, stage, age and comorbidity score,
respectively were tested and included in the final model if
approaching significance (p < 0.2). Additionally, multivari-
able regression models for competing risk analysis, using
the Fine and Gray approach, were developed and used to
assess the risk of death due to cancer from the estimated
sub-hazard ratios (SHR) [28]. There was no meaningful
difference between competing risk and disease-specific
Cox proportional hazards regression, hence only compet-
ing risk results are presented in this report.
To assess the utility of the PCSCI for explaining differ-
ences in survival by Aboriginality, the percentage change
in SHRs between restricted and unrestricted models
were computed for each index as follows, and compari-
sons made across indices:
[(SHR without comorbidity – SHR comorbidity)/ (SHR without
comorbidity − 1.0)] × 100
The study was reviewed and approved by the Human Re-
search Ethics Committees of South Australian Health, the
Aboriginal Health Council and University of South Australia.
The Cancer Data and Aboriginal Disparities (CanDAD) pro-
ject’s Aboriginal Community Reference Group (ACoRG)
were consulted to ensure acceptability of the study to
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Aboriginal people and alignment with South Australian
Aboriginal Health Research Accord principles [29].
Results
A total of 777 Aboriginal primary cancer cases (mean age
(standard deviation) = 57.7 years (± 15.6 years)), and 777
non-Aboriginal cases (mean age = 58.5 years (± 15.5 years))
were included in the matched cohort (Table 1). A higher
proportion of Aboriginal were diagnosed at a distant stage
(31.3% vs 22.0%), lived in outer regional and remote areas
(50.3% vs 19.6%) and lived in low socioeconomic areas
(55.5% vs 24.2%) compared with non-Aboriginal controls,
(p < 0.05). By the end of follow-up period, 59.3% of Abori-
ginal people had died of cancer compared to 43.8% of
non-Aboriginal controls (Table 1).
Development of a general population-based cancer-specific
comorbidity index (PCSCI)
Conditions included in the development of PCSCI and
the numbers (%) of cancer cases affected are shown in
Table 2. Hypertension (uncomplicated) and chronic ob-
structive pulmonary disease (COPD) were two of the
most common comorbid conditions in both Aboriginal
and non-Aboriginal cases, with a higher prevalence in
Aboriginal compared to non-Aboriginal people (13.5%
vs 7.1% for hypertension (uncomplicated) and 10.7% vs
4.4% for COPD) (Table 2). Although Aboriginal people
had a higher comorbidity level than non-Aboriginal
people, the assigned weights were generally lower for the
same comorbid conditions than those assigned for
non-Aboriginal people. PCSCI scores ranged from a low
of 0 to a high of 25 for the matched cohort, with 29%
having PCSCI score ≥ 1.
Internal validation of the index
All indices showed similar predictive accuracy for
all-cause and cancer-specific mortality (Table 3). The
C-index ranged from 0.678 to 0.727 for all models using
1-year all-cause mortality, with PCSCI having the highest
C-index score. Similarly, C-index score ranged from 0.689
to 0.733 for all models using 1-year cancer-specific mor-
tality. Again, the highest C-index score applying for the
PCSCI. The addition of the different comorbidity indices
into the baseline model resulted in significant improve-
ments in model fit, with PCSCI having a slightly lower
AIC, indicating better model performance (Table 3).
The utility of PCSCI in explaining variation in survival
Unadjusted competing risk regression modelling showed
that Aboriginal people had a higher risk of cancer death
than their non-Aboriginal counterparts (SHR = 1.96, 95%
CI; 1.71–2.24). After adjusting for stage, remoteness
area, areal level SES and comorbidity, Aboriginal people
still had elevated risk of cancer death, and this was
Table 1 Demographic and clinical characteristics of a matched
South Australian Aboriginal and non-Aboriginal cohort diagnosed




N (%) N (%) p-value
Age in years (mean, ± SD) 57.7 (± 15.6) 58.5 (± 15.5) p = 0.232
Sex
Male 375 (48.3) 375 (48.3)
Female 402 (51.7) 402 (51.7) p = 1.000
Decade of diagnosis
1990–1999 284 (36.6) 284 (36.6)
2000–2010 493 (63.5) 493 (63.5) p = 1.000
Area-level socioeconomic status
Q1 (Most disadvantaged) 431 (55.5) 188 (24.2)
Q2 156 (20.1) 167 (21.5)
Q3 76 (9.8) 129 (16.6)
Q4 68 (8.8) 146 (18.8)
Q5 (Least disadvantaged) 46 (5.9) 147 (18.9) p < 0.001
Geographic remoteness
Major cities 328 (42.2) 544 (70.0)
Inner regional 58 (7.5) 81 (10.4)
Outer regional 220 (28.3) 117 (15.1)
Remote 171 (22.0) 35 (4.5) p < 0.001
Degree of spread at diagnosis
Localised 289 (37.2) 390 (50.2)
Regional 155 (20.0) 132 (17.0)
Distant 243 (31.3) 171 (22.0)
Unknown/unstageable 90 (11.6) 84 (10.8) p < 0.001
Grouped primary sites
Head & neck 110 (14.2) 110 (14.2)
Gastrointestinal 162 (20.9) 162 (20.9)
Gynaecological 54 (7.0) 54 (7.0)
Genitourinary 11 (1.4) 11 (1.4)
Thoracic 124 (16.0) 124 (16.0)
Breast 78 (10.0) 78 (10.0)
Skin 34 (4.4) 34 (4.4)
Lympho haematopoietic 39 (5.0) 39 (5.0)
Prostate 45 (5.8) 45 (5.8)
Unknown primary 46 (5.9) 46 (5.9)
Other remaining sites 74 (9.5) 74 (9.5) p = 1.000
Vital status at 31/12/2013
Alive 220 (28.3) 349 (44.9)
Non-cancer death 96 (12.4) 88 (11.3)
Cancer death 461 (59.3) 340 (43.8) p < 0.001
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Table 2 Prevalence of comorbidities in South Australian population and association with 1-year all-cause mortality
Comorbidity n (%) Aboriginal aHR (95% CI)a weight n (%) non-Aboriginal aHR (95% CI) a weight
Alcohol abuse 77 (9.9) 1.73 (1.25–2.39) 2 13 (1.7) 1.07 (0.44–2.64) 1
AMI 32 (4.1) 1.24 (0.75–2.04) 1 8 (1.0) 0.68 (0.21–2.18) 0
Angina 38 (4.9) 1.21 (0.78–1.89) 1 13 (1.7) 2.48 (1.06–5.82) 2
Anxiety and behavioural disorders 14 (1.8) 1.08 (0.44–2.66) 1 8 (1.0) 1.46 (0.35–6.01) 1
Blood loss anaemia 11 (1.4) 1.42 (0.52–3.88) 1 ** ** **
Bowel disease 18 (2.3) 1.10 (0.54–2.25) 1 5 (0.6) 11.17 (3.73–33.5) 11
Cardiac arrhythmias 30 (3.9) 0.80 (0.46–1.41) 0 22 (2.8) 0.99 (0.46–2.14) 0
CHF 36 (4.6) 1.48 (0.96–2.28) 1 14 (1.8) 2.09 (1.00–4.37) 2
Chronic viral hepatitis 18 (2.3) 0.97 (0.45–2.10) 0 ** ** **
Coagulopathy 18 (2.3) 1.06 (0.46–2.41) 1 9 (1.2) 1.36 (0.42–4.49) 1
COPD 83 (10.7) 1.13 (0.81–1.59) 1 34 (4.4) 1.64 (0.92–2.90) 2
CVD 26 (3.4) 1.33 (0.74–2.40) 1 15 (1.9) 2.12 (1.07–4.13) 2
Deficiency anaemia 22 (2.8) 1.07 (0.56–2.01) 1 14 (1.8) 0.81 (0.29–2.27) 0
Dementia 6 (0.8) 0.67 (0.16–2.72) 0 ** ** **
Depression 20 (2.6) 1.00 (0.49–2.04) 1 9 (1.2) 1.14 (0.28–4.64) 1
Diabetes complicated 58 (7.5) 1.13 (0.76–1.68) 1 6 (0.8) 1.27 (0.17–9.31) 1
Diabetes without complications 84 (10.8) 1.01 (0.72–1.42) 1 21 (2.7) 2.67 (1.39–5.13) 3
Drug abuse 29 (3.7) 0.97 (0.54–1.75) 0 6 (0.8) 2.34 (0.73–7.52) 2
Epilepsy 13 (1.7) 1.26 (0.55–2.88) 1 6 (0.8) 4.11 (1.27–13.3) 4
Eye problems 16 (2.1) 1.50 (0.83–2.70) 1 ** ** **
Fluid and electrolyte disorders 18 (2.3) 1.43 (0.75–2.71) 1 9 (1.2) 3.22 (1.40–7.38) 3
Hypertension uncomplicated 105 (13.5) 1.01 (0.74–1.38) 1 55 (7.1) 1.07 (0.63–1.80) 1
Hypothyroidism 12 (1.5) 1.77 (0.78–4.04) 2 ** ** **
Intestinal disorders 14 (1.8) 0.86 (0.35–2.12) 0 15 (1.9) 0.58 (0.18–1.85) 0
Joint and spinal disorders 5 (0.6) 2.62 (0.64–10.8) 3 ** ** **
Metabolic disorders 48 (6.2) 1.31 (0.88–1.95) 1 13 (1.7) 0.87 (0.32–2.36) 0
Mild liver disease 24 (3.1) 2.00 (1.17–3.40) 2 ** ** **
Moderate/Severe liver disease ** ** ** 6 (0.8) 3.23 (1.29–8.05) 3
Obesity 17 (2.2) 0.61 (0.22–1.64) 0 ** ** **
Osteoporosis 6 (0.8) 0.82 (0.26–2.59) 0 ** ** **
Other cardiac conditions 58 (7.5) 1.34 (0.92–1.95) 1 14 (1.8) 2.97 (1.35–6.56) 3
Other neurological disorders 11 (1.4) 0.90 (0.28–2.85) 0 ** ** **
Pancreatitis 6 (0.8) 0.80 (0.20–3.23) 0 ** ** **
Paralysis 13 (1.7) 1.89 (0.83–4.30) 2 9 (1.2) 2.31 (1.06–5.02) 2
Peptic ulcer 18 (2.3) 0.95 (0.46–1.94) 0 15 (1.9) 1.25 (0.51–3.09) 1
Psychoses 23 (3) 1.43 (0.75–2.72) 1 8 (1.0) 1.10 (0.27–4.46) 1
Pulmonary circulation disorders 7 (0.9) 0.79 (0.29–2.20) 0 ** ** **
PVD 6 (0.8) 0.23 (0.03–1.67) 0 6 (0.8) 1.23 (0.30–5.02) 1
Renal disease 34 (4.4) 2.37 (1.55–3.62) 2 5 (0.6) 8.56 (2.53–28.9) 9
Rheumatoid disease 7 (0.9) 1.77 (0.65–4.84) 2 6 (0.8) 1.77 (0.65–4.84) 2
Sleep disorders 5 (0.6) 1.91 (0.60–6.08) 2 ** ** **
Urinary tract disorders 7 (0.9) 2.19 (0.87–5.52) 2 ** ** **
Valvular diseases 13 (1.7) 1.48 (0.65–3.39) 1 6 (0.8) 1.46 (0.20–10.7) 1
Weight loss 17 (2.2) 2.97 (1.71–5.16) 3 7 (0.9) 1.21 (0.30–4.94) 1
Abbreviations: AMI acute myocardial infarction, COPD chronic obstructive pulmonary diseases, CVD cerebrovascular disease, CHF congestive heart failure
aadjusted for age, sex, stage, primary site
**excluded from the model, prevalence = < 0.5%
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significant for all indices, although there were not large
differences in the reduction of death between indices
(Table 4). There was a reduction in the risk of
cancer-specific mortality after adjusting for area level SES,
remoteness and stage, although the risk remained higher
for Aboriginal people (SHR = 1.60, 95% CI; 1.34–1.92)
(Table 4).
The addition of comorbidity indices: CCI, WECI, C3,
and PCSCI to the adjusted model reduced the SHR for
Aboriginality by 10%, 5%, 10% and 12% respectively for
cancer-specific mortality. Interactions between Aborigi-
nality and area remoteness, and area level SES and age
were not statistically significant. There was a significant
interaction, however, between Aboriginality and comor-
bidity. This suggests that Aboriginal survival is modified
disproportionately by comorbidity, with an increase in
comorbidity score resulting in poorer survival.
Discussion
As comorbidity is prevalent in cancer populations, and
particularly in Aboriginal people, it is important when
adjusting for its effects, that the best measure of
comorbidity is used. In this study, there were slight differ-
ences in type of comorbidities between Aboriginal and
non-Aboriginal people, with the prevalence generally being
higher in Aboriginal people. The most common comorbid
conditions found in this study for Aboriginal cases were
the same as reported in previous studies [9, 10]. The two
most common comorbid conditions in both populations
were “uncomplicated” hypertension and COPD. This is a
key finding for policy makers as it implies that proposed/
planned interventions for these conditions would be ap-
plicable for both Aboriginal and non-Aboriginal cases.
Although Aboriginal people had a higher prevalence of
comorbidity, the weights assigned to comorbid condi-
tions were generally lower indicating that their impact
on mortality was less severe than for non-Aboriginal
cases. Also, weights assigned to comorbid conditions in
the customised index of this study differed with those in
three comparison indices, for the same comorbid condi-
tions, potentially due to these conditions having a differ-
ent mortality impact. Given the advances in treatment
and management of chronic conditions, their contribu-
tion to the risk of mortality could have changed. This is
consistent with a study by Quan et al. [30] which found
reduced weights for some Charlson comorbid condi-
tions. Furthermore, only 12 conditions were still predict-
ive of mortality compared to 17 from the original CCI.
However, results need to be interpreted with caution
as the matched non-Aboriginal cohort may not be repre-
sentative of the South Australian non-Aboriginal popula-
tion. Also, of note are the very large weights for bowel
disease and renal failure in the non-Aboriginal cohort,
which could be due to unstable estimates resulting from
small numbers. By the end of 1-year follow up, all cases
had died from all causes.
When weights were summed to get the overall PCSCI
score, more people were identified as having a score
greater than 0, compared to comparison indices. This in-
dicates that generic indices can potentially underesti-
mate the prevalence of comorbidity when applied in this
Table 3 Internal validation and comparison of indices in predicting
1-year mortality in a matched cohort
All-cause mortality Cancer specific mortality
Models c-index AIC c-index AIC
BLa 0.678 428 0.689 376
BL + PCSCI 0.727 411 0.733 360
BL+ CCI 0.716 413 0.724 362
BL +WECI 0.719 416 0.724 368
BL + C3 0.720 420 0.731 366
Abbreviations: BL baseline, CCI Charlson comorbidity index, WECI weighted
Elixhauser comorbidity index, C3 cancer care and comorbidity index, PCSCI
Population cancer specific comorbidity index
aBaseline model adjusted for age, stage, stratified by (sex, year of birth, year of
diagnosis and primary site)
bBold entries represent best models
Table 4 Competing risk regression of factors associated with
risks of cancer death, SA 1990–2010
Aboriginal – Yes SHR (95% CI)
Unadjusted 1.96 (1.71–2.24)
Baseline modela 1.60 (1.34–1.92)
PCSCI
Baseline modela 1.60 (1.34–1.92)
Adjusted for PCSCI 1.53 (1.28–1.83)
Proportion explained by comorbidity for
the effect of Aboriginality on survival
12%
CCI
Baseline modela 1.60 (1.34–1.92)
Baseline modela + CCI 1.54 (1.28–1.84)
Proportion explained by comorbidity for
the effect of Aboriginality on survival
10%
ECI
Baseline modela 1.60 (1.34–1.92)
Adjusted for ECI 1.57 (1.31–1.87)
Proportion explained by comorbidity for
the effect of Aboriginality on survival
5%
C3
Baseline modela 1.60 (1.34–1.92)
Adjusted for C3 1.54 (1.29–1.85)
Proportion explained by comorbidity for
the effect of Aboriginality on survival
10%
Abbreviations: SHR Sub hazard ratio, CCI Charlson comorbidity index,WECI weighted
Elixhauser comorbidity index, C3 cancer care and comorbidity index, PCSCI Population
cancer specific comorbidity index
aBaselines model adjusted for stage, remoteness area and SES
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population. This could be due to these indices including
fewer conditions than the PCSCI; or alternatively, differ-
ences in comorbidity profiles of Aboriginal people com-
pared to the general population. This finding further
underscores the potential desirability of customised,
population-specific comorbidity indices.
When PCSCI was validated and compared to other in-
dices, however, results indicated only marginally better
discrimination of the customised index than generic in-
dices. These findings are nonetheless consistent with
those of previous studies and suggestions that custom-
ized indices would provide more accurate measures and
enable better adjustment for comorbidity [12, 13, 31].
Further improvements may be seen if individual comor-
bid conditions, rather than a summary measure, were
used for adjustment in survival analyses.
When PCSCI was compared to a cancer-specific index,
C3, it marginally outperformed it. One of the advantages
of PCSCI over C3 is in its development where Aboriginal-
ity was taken into account when deriving weights for co-
morbidities. As such, PCSCI can be used flexibly for risk
adjustments in both Aboriginal only and matched Abori-
ginal and non-Aboriginal cohorts. Also, incorporating
Aboriginal status in weight development makes this index
more representative of an Aboriginal cancer population,
more accurate and with greater ability to adjust for co-
morbidity (as compared to C3 which was not developed
with an Australian Aboriginal cohort in mind).
After accounting for degree of spread (summary stage),
remoteness and socioeconomic status, the increased risk
of cancer death in Aboriginal people remained. The
addition of PCSCI and other indices led to a reduction of
this disparity by between 5 and 12%, with a slightly higher
reduction occurring with the PCSCI. Further investiga-
tions are needed to determine whether the differences in
survival, which persisted after comorbidity adjustment,
could be explained by other factors known to impact on
survival but not included in the study, for example, life-
style factors or adherence to treatment guidelines.
Lack of access to treatment data in this study limited
our ability to investigate possible reasons for differences
in mortality. Due to a small number of cases within each
cancer site group, we could not test whether weights de-
rived for each comorbid condition would differ by can-
cer type, which could influence overall comorbidity
scores. Another limitation was not having access to
Medicare data. It is envisaged that having access to
Medicare data for this study population could potentially
strengthen our index, as more comorbid conditions
which might impact on mortality risk could be inferred
and added to the patient’s total score (including condi-
tions not associated with hospitalisation).
The greatest strengths of this study were accessing data
where Aboriginal status was cross-validated and were the
sample of cases was drawn from the entire Aboriginal co-
hort diagnosed with cancer in South Australia for the
period under review, thus minimising the potential for se-
lection bias. The PCSCI was developed in South Australia,
and it is recommended that PCSCI be validated in an ex-
ternal Aboriginal population to assess its generalizability
to Aboriginal populations in other Australian states. The
availability of comparable data for linking at a population
level throughout Australia underscores the usefulness of
data linkage to inform policy and to provide evidence of
risk factors which impact on cancer outcomes.
In conclusion, our study is the first to develop a comor-
bidity index specific to cancer population of South Australia
which can be applied effectively to Aboriginal only or a
combined population. The results showed that PCSCI per-
formed as well as or marginally better than CCI, ECI and
C3. Nonetheless results also indicate that generic comorbid-
ity indices developed in other non-Aboriginal populations
probably provide a reasonably accurate determinations of
comorbidity effects in Aboriginal people with cancer.
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